Analysts focus on three programs in big year for Bristol Myers

Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by the end of 2026, in ...